![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Issues Advice on Replacement or Corrective Therapies for Certain Rare Diseases
FDA Issues Advice on Replacement or Corrective Therapies for Certain Rare Diseases
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
July 27, 2018
The FDA published a draft guidance recommending ways to demonstrate if new drugs or drug uses are effective for certain low-prevalence rare diseases caused by single enzyme defects.
The guidance applies to diseases that have well-characterized pathophysiology and whose changes in substrate deposition can be effectively measured in the affected tissues; it does not apply to rare diseases that progress rapidly.
“There are many reasons that make demonstration of effectiveness extremely challenging for drugs intended to treat slowly progressive, low-prevalence rare diseases that result from defects in a single enzyme,” the agency said.
Upcoming Events
-
21Oct